Does Rallies show Form 4 insider transactions for SLS?

Yes. Rallies tracks SLS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SLS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SLS. It does not provide personalized investment advice.

SLS (SELLAS) Stock Analysis - Insider Trades

SELLAS (SLS) is a publicly traded Healthcare sector company. As of May 21, 2026, SLS trades at $8.91 with a market cap of $1.36B and a P/E ratio of -35.77. SLS moved +18.58% today. Year to date, SLS is +79.40%; over the trailing twelve months it is +362.37%. Its 52-week range spans $0.77 to $9.10. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces SLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SLS stock inside the company?

Recent SLS insider activity includes Kalin Katherine Bach bought 63.40K, VAN NOSTRAND ROBERT L bought 10.00K, Wasman Jane bought 20.00K, Kalin Katherine Bach bought 20.00K, and Stergiou Angelos M. sold 6.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SLS Key Metrics

Key financial metrics for SLS
Metric	Value
Price	$8.91
Market Cap	$1.36B
P/E Ratio	-35.77
EPS	$-0.25
Dividend Yield	0.24%
52-Week High	$9.10
52-Week Low	$0.77
Volume	300.81K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-26.86M
Gross Margin	0.00%

Recent SLS Insider Trades

Kalin Katherine Bach bought 63.40K (~$100.81K) on Nov 19, 2025.
VAN NOSTRAND ROBERT L bought 10.00K (~$14.80K) on Jun 12, 2025.
Wasman Jane bought 20.00K (~$33.80K) on May 30, 2025.
Kalin Katherine Bach bought 20.00K (~$36.00K) on May 22, 2025.
Stergiou Angelos M. sold 6.49K (~$16.94K) on Dec 5, 2022.

Latest SLS News

SELLAS Life Sciences Hits 72 of 80 Trial Events and Doses First AML Patient with $114M Cash — Mar 19, 2026
Sellas to Showcase SLS009 Potent CDK9 Inhibitor Lowering AML Cell IC50 to 20nM — Mar 17, 2026
SELLAS Life Sciences Shares Rally 364% Over Year as ORR Hits 46% — Mar 4, 2026

SLS Analyst Consensus

2 analysts cover SLS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about SLS

Who is trading SLS stock inside the company?: Recent SLS insider activity includes Kalin Katherine Bach bought 63.40K, VAN NOSTRAND ROBERT L bought 10.00K, Wasman Jane bought 20.00K, Kalin Katherine Bach bought 20.00K, and Stergiou Angelos M. sold 6.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SLS?: Yes. Rallies tracks SLS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SLS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SLS. It does not provide personalized investment advice.